Lee N. Newcomer, MD, MHA

Lee N. Newcomer, MD, MHA, senior vice president for Oncology, Genetics and Women's Health at UnitedHealthcare, spoke on Defining and Measuring Quality Outcomes in Oncology.

Lee N. Newcomer, MD, MHA, joined the response panel, Challenges and Opportunities for Quality Measures in Oncology.

A lively discussion on Foundation Medicine's approach to creating genomic profiles.

Mr Klein leads another discussion with Michael Kolodjiez, MD, Lee N. Newcomer, MD, MHA, John L. Fox, MD, MHA, and Jerry Conway. The panel responds to whether there are gaps in targeted gene analyses. They also discuss other issues including bioinformatics, and how payers, providers, and pharmacists might collaborate on improving care through genetic sequencing.

Dr Klein begins the panel discussion by asking participants to name one of their biggest challenges. Dr Newcomer responds that time and the fact that there are not enough PhDs are challenging. Ms Torda suggests that standardized data and data collection remains difficult. Dr Scanlon says it's the nimbleness of structuring data.

Dr Newcomer says that he welcomes the transition of oncology from being evaluated in process measures to outcome measures. He says that while quality measures can be quick and messy, these results are used for the purpose of finding gaps and seeing if those gaps can be improved.

Radical Changes in Payment Incentives and Elimination of Low-Value Care

Healthcare coverage is simply unaffordable for too many people. It will only become affordable with radical changes in payment incentives and elimination of care that doesn%u2019t really matter.